Isotretinoin Pregnancy Prevention: US and UK Rules

Isotretinoin pregnancy prevention rules have one shared goal: the medicine must not be used during pregnancy. In the US, iPLEDGE requires enrollment, pregnancy testing and either two approved contraceptive methods or continuous abstinence. In the UK, the Pregnancy Prevention Programme uses risk-based groups. When contraception is required, both systems start it at least one month before treatment and continue it for one month after the last dose.

The details differ enough to cause missed prescriptions. This guide reflects official rules checked on 28 October 2026. Your clinic's instructions still control your care.

Why pregnancy prevention is required

Accutane is a familiar brand name for oral isotretinoin. The rules apply to prescribed oral isotretinoin products, whatever brand appears on the box.

Taking isotretinoin during pregnancy can cause miscarriage and severe birth defects. The iPLEDGE Prescriber Guide says exposure can cause harm even for a short period. The UK product information also treats pregnancy as an absolute contraindication.

This is why a negative test alone isn't enough. It only shows the result at one point in time. The programs combine testing, contraception or documented abstinence, counseling and controlled dispensing.

These safeguards don't decide whether isotretinoin suits your acne. The separate guide on when clinicians consider isotretinoin explains the treatment threshold.

Isotretinoin pregnancy prevention: US vs UK

What iPLEDGE requires in the US

iPLEDGE separates patients into those who can and cannot become pregnant. Everyone enrolls, but the pregnancy-prevention steps apply to the first group. The category follows reproductive potential, not gender identity.

Before the first prescription

The 2023 iPLEDGE Prescriber Guide requires a negative screening test at enrollment. A second negative test follows at least 30 days later, after one month of contraception or continuous abstinence. Both tests must take place in a medical setting.

If you use contraception, iPLEDGE normally requires one primary and one secondary method. You use both for one month before treatment, throughout treatment and one month after. Continuous abstinence is the program's alternative when it accurately describes your situation.

Each month and after the last dose

Each month, the prescriber records counseling, the test result and the chosen methods. You then answer iPLEDGE questions before the pharmacy can dispense a 30-day supply. The seven-day window begins when the test specimen is collected, not when the prescription reaches the pharmacy.

The FDA is currently using enforcement discretion for testing during and after treatment. Your prescriber may accept a home test if they have a process to reduce mistakes or falsified results. The two pre-treatment tests still need a medical setting.

A rule change is close. The FDA says revised iPLEDGE requirements are due to start on 15 November 2026. They will formally allow prescriber-approved home testing during and after treatment and remove the 19-day lockout after a missed first window.

Those changes were delayed once. Until the revised system is live, ask your clinic what the portal currently requires. Don't assume an announced change has already reached the pharmacy.

What the UK Pregnancy Prevention Programme requires

The MHRA's February 2026 form places patients with childbearing potential into three practical groups. Your prescriber records the group and reviews it with you.

• Group A covers an agreed expectation of no pregnancy risk. Examples include long-term abstinence or sex only with someone who cannot cause pregnancy. Contraception and pregnancy testing aren't required while that remains true.
• Group B covers an implant, IUD or IUS in place for at least four weeks. It requires a negative test before treatment, testing at follow-ups and a test one month after stopping.
• Group C covers a hormonal pill or injection plus a barrier method. It uses the same testing stages, but prescriptions remain limited to 30 days.

For groups A and B, the MHRA form allows prescriptions up to 12 weeks once treatment is stable. The prescriber may still choose shorter supplies for monitoring.

The Ennogen UK Summary of Product Characteristics, updated in May 2026, recommends regular follow-ups, ideally monthly. It says the need for a test every month depends on sexual activity, menstrual history, contraception and local practice. The MHRA's October 2025 guidance allows a remotely observed test to count as medically supervised when the clinic provides suitable oversight. The first consultation should still be in person.

An older UK rule required two prescribers to approve treatment for patients under 18. The MHRA removed that requirement on 22 January 2026. Other safety checks remain, including the signed risk form and monitoring during treatment.

If contraception fails or pregnancy is possible

Don't wait for the next scheduled test. Contact your prescriber or dermatology team straight away after unprotected sex, a contraceptive failure, a missed period or a positive test. Ask a pharmacist or sexual-health service promptly about emergency contraception after a pregnancy-risk event.

Both official programmes direct a patient who is pregnant, or thinks they may be pregnant, to stop isotretinoin and seek medical advice immediately. Tell the clinician when the last dose and risk event occurred. Don't share capsules or donate blood during treatment or for one month afterwards.

Questions to settle before the first prescription

This checklist is an editorial aid, not a programme form. Write the answers down before you leave the appointment.

• Which pregnancy-potential category or UK PPP group has the prescriber recorded?
• Which contraception or abstinence plan is documented, and when does the one-month lead-in finish?
• Who orders each test, and can a supervised home test count in your clinic?
• Which date starts the dispensing window, and when does that window close?
• Who should you contact after hours if contraception fails or a test is positive?

Pregnancy prevention is one part of isotretinoin care. Blood tests may check liver enzymes and blood fats, but schedules aren't universal. UK rules also require mental-health and sexual-function monitoring. Current product information says not to combine isotretinoin with tetracyclines or vitamin A supplements, so disclose every drug and supplement.

Dry lips and skin are common, while some symptoms need prompt advice. Read what happens month by month on isotretinoin, how clinicians approach blood-test monitoring, and which side effects need prompt medical advice.